- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Shoppers Drug Mart report: Allowing pharmacists in Canada to immunize could save lives, money
- Study: Whooping cough vaccine may not prevent infection
- Study: Pharmacist intervention improves shingles vaccine rate
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
NEW YORK — The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.
Pfizer announced the approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for children and adolescents ages 6 years to 17 years for active immunization against the 13 Streptococcus pneumonia serotypes the vaccine covers. For this group, Prevnar 13 is administered as a one-time dose to patients who have never received it.
The approval was the result of an FDA review of a phase-3 trial of the vaccine in 592 older children and adolescents, including those with asthma.